Recombinant Human N-Myc Proto-Oncogene Protein (MYCN) Protein (His)

Name: Recombinant Human N-Myc Proto-Oncogene Protein (MYCN) Protein (His)
Brand: Beta LifeScience
SKU: BLC-07871P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description	Recombinant Human N-Myc Proto-Oncogene Protein (MYCN) Protein (His) is produced by our Baculovirus expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P04198
Target Symbol	MYCN
Species	Homo sapiens (Human)
Expression System	Baculovirus
Tag	N-6His
Target Protein Sequence	MPSCSTSTMPGMICKNPDLEFDSLQPCFYPDEDDFYFGGPDSTPPGEDIWKKFELLPTPPLSPSRGFAEHSSEPPSWVTEMLLENELWGSPAEEDAFGLGGLGGLTPNPVILQDCMWSGFSAREKLERAVSEKLQHGRGPPTAGSTAQSPGAGAASPAGRGHGGAAGAGRAGAALPAELAHPAAECVDPAVVFPFPVNKREPAPVPAAPASAPAAGPAVASGAGIAAPAGAPGVAPPRPGGRQTSGGDHKALSTSGEDTLSDSDDEDDEEEDEEEEIDVVTVEKRRSSSNTKAVTTFTITVRPKNAALGPGRAQSSELILKRCLPIHQQHNYAAPSPYVESEDAPPQKKIKSEASPRPLKSVIPPKAKSLSPRNSDSEDSERRRNHNILERQRRNDLRSSFLTLRDHVPELVKNEKAAKVVILKKATEYVHSLQAEEHQLLLEKEKLQARQQQLLKKIEHARTC
Expression Range	1-464aa
Protein Length	Full Length
Mol. Weight	50.6 kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Positively regulates the transcription of MYCNOS in neuroblastoma cells.
Subcellular Location	Nucleus.
Database References	HGNC: 7559 OMIM: 164280 KEGG: hsa:4613 STRING: 9606.ENSP00000281043 UniGene: Hs.25960
Associated Diseases	Feingold syndrome 1 (FGLDS1)
Tissue Specificity	Expressed in the neuronal cells of the cerebrum, neuroblastomas and thyroid tumors (at protein level).

Gene Functions References

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. PMID: 30451831
This suggested that NMyc regulated survival and growth of CHP134 and BE2C neuroblastoma cells, potentially through Wnt/betacatenin signaling. Furthermore, associated proteins, NMyc and STAT interactor and dickkopf Wnt signaling pathway inhibitor 1, were demonstrated to be involved in this regulation. PMID: 29749516
In this report, we present a case with Feingold Syndrome having a novel mutation in MYCN gene and discuss genetic counselling and prenatal diagnosis due to pregnancy of the patient's mother. PMID: 30204967
Results demonstrated that MYCN expression was downregulated in cholangiocarcinoma (CCA) through a mechanism involving miR-5095 binding its 3'UTR. PMID: 29620172
MYCN levels are regulated transcriptionally by MYCNOS-01 (an alternative transcript of MYCNOS) in rhabdomyosarcoma and neuroblastoma cells. PMID: 29466962
a MycN/CIP2A-mediated cell-fate bias may reflect a possible mechanism underlying early priming of some aggressive forms of neuroblastoma. PMID: 30021854
CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma. PMID: 29322842
Data indicate that inter-play between MYCN and the highly tumorigenic proteins which are upregulated in the malignant IMR-32 neuroblastoma cells may be fueling their aggressive behavior. PMID: 29328367
these results suggest that MYCN serves as a prognostic biomarker and therapeutic target of ACR for liver cancer stem cell in de novo Hepatocellular carcinoma. PMID: 29686061
Alternative nonhomologous DNA end-joining pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation have been revealed in the process of neuroblastoma initiation in mice. PMID: 29238067
High TrkA expression is one of the most powerful predictor of good prognosis in neuroblastoma and is associated with younger age, lower stage, and absence of MYCN amplification PMID: 29018959
overexpression of MYCN promoted cell proliferation, and induced erythroid differentiation block and apoptosis resistance to cytotoxic agent. Knockdown of MYCN inhibited the expression of EZH2, and then activated p21 expression through removal of H3K27me3 at the p21 promoter. PMID: 29022893
MAX to MYCN ratio that can account for tumour progression and clinical outcome in neuroblastoma. PMID: 29408445
MYCN expression is regulated by ZAR1 in neuroblastoma. PMID: 28791558
The target of miR-29b was predicted using miRanda, TargetScan and PicTar sofeware and authors also found MYCN was a direct target of miR-29b in glioma cells and miR-29b inhibited the proliferation of glioma cells via MYCN dependent way. PMID: 28423357
eEF2K protects MYCN overexpressing NB cells from ND in vitro and in vivo, highlighting this kinase as a critical mediator of the adaptive response of MYCN amplified NB cells to metabolic stress. PMID: 28574509
Among 30 samples of brain tumor, 14 cases revealed MYCN amplification. High-protein expression of MYCN was also observed in 43.3% of patients. There was a significant correlation between MYCN gene amplification and protein expression, interestingly five case showed discrepancy between the gene amplification and protein expression. PMID: 28453467
PRMT1 has a role in regulating MYCN in neuroblastoma PMID: 27571165
N-myc levels appear to be modulated by the antagonistic interactions of both miR-17, as a negative regulator, and HuD, as a positive regulator in N-myc-amplified neuroblastoma cells. PMID: 28560387
We also propose a model for the stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCF(FbxW7) to disfavor the generation of Lys48-linked polyubiquitin chains PMID: 27837025
This study provides a novel insight for miR-221 in the control of neuroblastoma cell proliferation and tumorigenesis, suggesting potentials of miR-221 as a prognosis marker and therapeutic target for patients with MYCN overexpressing neuroblastoma. PMID: 28003306
N-MYC is in the downstream-regulated gene family in reprogramming cancer metabolism under hypoxia [review] PMID: 27447861
SNHG1 is up-regulated by MYCN amplification and could be a potential prognostic biomarker for high-risk neuroblastoma intervention. PMID: 27517149
MYCN expression is a marker indicative of likely clinical sensitivity to mTOR inhibition in neuroblastoma cells PMID: 27438153
Results show that MYCN and LSD1 co-localize at NDRG1 promoter and repress its expression in neuroblastoma cells. PMID: 27894074
Data indicate cross-talks between MYCN and beta-catenin signalling, which repress normal beta-catenin mediated transcriptional regulation. PMID: 27531891
Data show that transcription factor activating enhancer binding protein-4 (TFAP4) is a direct transcriptional target of MYCN in neuroblastoma and that high levels of this transcription factor are associated with poor clinical outcome in this disease. PMID: 27448979
data extend knowledge on roles of MCPIP1 in our model and link the protein to regulation of expression and stability of MYCN through decrease of signaling via Akt/mTOR pathway. PMID: 27935099
Data show that MYCN and its regulated microRNAs acted together to repress the tumor suppressor genes. PMID: 27167114
Common genetic variation predisposes to different neuroblastoma genotypes, including the likelihood of somatic MYCN-amplification. [meta-analysis] PMID: 29117357
Results establish evidence that high MYCN amplification can be present in retinoblastoma with or without coding sequence mutations in the RB1 gene. PMID: 28211617
The study conducted metabolic profiling of pre-malignant sympathetic ganglia and tumors derived from the TH-MYCN mouse model of neuroblastoma, that overexpresses human MYCN and compared to non-malignant ganglia from wildtype littermates. These results identify enhanced glutathione biosynthesis as a selective metabolic adaptation required for initiation of MYCN-driven neuroblastoma. PMID: 26996379
Many prognostic signatures for neuroblastoma are confounded by MYCN amplification. PMID: 27599694
Increasing MYCN copy number is associated with an increasingly higher rate of unfavorable clinical/biological features, with 11q aberration being an exception. Patients with MYCN gain appear to have inferior outcomes, especially in otherwise more favorable groups. PMID: 28696504
miR-21 enhances chemo-resistance in tongue cancer cells via directly targeting CADM1, and an inverse correlation between miR-21 and CADM1 expression in vivo. MiR-21 overexpression is attributed to MYCN-mediated transcriptional regulation, which is also predictive for a worse prognosis in tongue cancer PMID: 27055844
LMO1 is an important oncogene that promotes neuroblastoma initiation, progression, and widespread metastatic dissemination. PMID: 28867147
our results identify DOT1L as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. PMID: 28209620
CCCTC-binding factor (CTCF) targets the binding sites within MYCN promoter to facilitate its expression in neuroblastoma (NB) cells. PMID: 26549029
PAX3-FOXO1 collaborates with MYCN during early rhabdomyosarcoma (RMS) tumourigenesis to dysregulate proliferation and inhibit myogenic differentiation and cell death. PMID: 28138962
The findings reveal a PLK1-Fbw7-Myc signaling circuit that underlies tumorigenesis and validate PLK1 inhibitors, alone or with Bcl2 antagonists, as potential effective therapeutics for MYC-overexpressing cancers. PMID: 27773673
Results show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC. PMID: 27728805
Rac activity may be an important determinant of metastatic capability in subsets of neuroblastoma cells lacking MYCN amplification. PMID: 27224546
MYCN Gene Amplification is associated with Neuroblastoma. PMID: 27513929
MYCN overexpression combined with activated anaplastic lymphoma kinase (ALK) is sufficient to induce neuroblastoma (NB) in mouse sympathoadrenal cells PMID: 27707976
MYCN amplification can be heterogeneous between tumor sites, during tumor progression or following treatment, challenging the notion that MYCN copy number does not change for a particular neuroblastoma. PMID: 27465929
High MycN expression is associated with low radiosensitivity in neuroblastoma. PMID: 27432152
applying loss-and-gain function analysis, we demonstrated that miR-34a directly targeted to MYCN to sensitize NSCLC cells to cisplatin. In addition, p53 was found to monitor the expression of miR-34a in NSCLC cells after cisplatin treatment. Therefore, the sensitivity of cisplatin in NSCLC cells was modulated via p53/miR-34a/MYCN axis. PMID: 27836543
Data supports our hypothesis that a positive-feedback loop of sonic hedgehog signaling induced INSM1 through N-myc and INSM1 enhanced N-myc stability contributing to the transformation of human neuroblastoma. PMID: 26456864
Data show that v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) was overexpressed in non-small cell lung cancer (NSCLC) tumor tissues and cell lines, suggesting that targeting MYCN might provide beneficial effects for the clinical therapy of NSCLC. PMID: 27449038
That initial decision to deny coverage could have had untoward health implications for this child, as the identification of constitutional MYCN duplication necessitated surveillance imaging for a number of pediatric malignancies associated with MYCN PMID: 27794475

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.